HMG CoA reductase inhibitors (statins) for dialysis patients (Withdrawn Paper, art. no. CD004289, 2009)

被引:13
作者
Navaneethan, Sankar D. [1 ]
Nigwekar, Sagar U. [2 ]
Perkovic, Vlado [3 ]
Johnson, David W. [4 ]
Craig, Jonathan C. [5 ]
Strippoli, Giovanni F. M. [5 ]
机构
[1] Cleveland Clin, Glickman Urol & Kidney Inst, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA
[2] Univ Rochester, Sch Med & Dent, Rochester Gen Hosp, Rochester, NY USA
[3] George Inst Int Hlth, Div Renal, Camperdown, NSW, Australia
[4] Princess Alexandra Hosp, Dept Nephrol, Woolloongabba, Qld 4102, Australia
[5] Childrens Hosp Westmead, Ctr Kidney Res, Westmead, NSW, Australia
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2009年 / 02期
关键词
CHRONIC KIDNEY-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN; LOW-DOSE ASPIRIN; HEMODIALYSIS-PATIENTS; HYPERCHOLESTEROLEMIC PATIENTS; PERITONEAL-DIALYSIS; META-REGRESSION; RISK-FACTORS;
D O I
10.1002/14651858.CD004289.pub3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase inhibitors (statins) in the treatment of dyslipidaemia in dialysis patients is unclear and their safety has not been established. Objectives To assess the benefits and harms of statins in peritoneal dialysis (PD) and haemodialysis patients (HD). Search strategy We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials (CENTRAL, in The Cochrane Library), the Cochrane Renal Group's specialised register and handsearched reference lists of textbooks, articles and scientific proceedings. Selection criteria Randomised controlled trials (RCTs) and quasi-RCTs comparing statins with placebo, no treatment or other hypolipidaemic agents in dialysis patients. Data collection and analysis Two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random effects model after testing for heterogeneity. The results were expressed as mean difference (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI). Main results Fourteen studies (2086 patients) compared statins versus placebo or other lipid lowering agents. Compared to placebo, statins did not decrease all-cause mortality (10 studies, 1884 patients; RR 0.95, 95% CI 0.86 to 1.06) or cardiovascular mortality (9 studies, 1839 patients: RR 0.96, 95% CI 0.65 to 1.40). There was a lower incidence of nonfatal cardiovascular events with statins compared to placebo in haemodialysis patients (1 study, 1255 patients; RR 0.86, 95% CI 0.74 to 0.99). Compared with placebo, statin use was associated with a significantly lower end of treatment average total cholesterol (14 studies, 1823 patients; MD -42.61 mg/dL, 95% CI -53.38 to -31.84), LDL cholesterol (13 studies, 1801 patients; MD -43.06 mg/dL, 95% CI -53.78 to -32.35) and triglycerides (14 studies, 1823 patients: MD -24.01 mg/dL, 95% CI -47.29 to -0.72). There was similar occurrence of rhabdomyolysis and elevated liver function tests with statins in comparison to placebo. Authors' conclusions Statins decreased cholesterol levels in dialysis patients similar to that of the general population. With the exception of one study, studies were of short duration and therefore the efficacy of statins in decreasing the mortality rate is still unclear. Statins appear to be safe in this high-risk population. Ongoing studies should provide more insight about the efficacy of statins in reducing mortality rates in dialysis patients.
引用
收藏
页数:84
相关论文
共 77 条
[1]  
Akcicek F, 1996, ADV PERIT D, V12, P261
[2]  
[Anonymous], MAST LIST J BEING SE
[3]  
[Anonymous], J SHOWA MED ASS
[4]  
[Anonymous], 4 INT COCHR C OCT 20
[5]  
[Anonymous], COCHRANE DATABASE SY
[6]  
[Anonymous], 38 C EUR REN ASS EUR
[7]  
[Anonymous], 6 AS PAC C NEPHR 199
[8]  
[Anonymous], ISN 13 INT C NEPHR 1
[9]  
[Anonymous], B HUNAN MED U
[10]  
[Anonymous], J AM SOC NEPHROLOGY